Edgewise Therapeutics Inc... (EWTX)
28.91
1.39 (5.05%)
At close: Jan 14, 2025, 3:59 PM
Company Description
Edgewise Therapeutics, Inc., a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases.
The Company's lead product candidate, EDG-5506, is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy which has completed Phase 1 clinical trial.
It develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders.
Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.
Edgewise Therapeutics Inc.
| Country | United States |
| IPO Date | Mar 26, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 108 |
| CEO | Dr. Kevin Koch Ph.D. |
Contact Details
Address: 3415 Colorado Avenue Boulder, Colorado United States | |
| Website | https://www.edgewisetx.com |
Stock Details
| Ticker Symbol | EWTX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001710072 |
| CUSIP Number | 28036F105 |
| ISIN Number | US28036F1057 |
| Employer ID | 82-1725586 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Kevin Koch Ph.D. | President, Chief Executive Officer & Director |
| R. Michael Carruthers | Chief Financial Officer |
| Dr. Alan J. Russell Ph.D. | Co-Founder, Chief Scientific Officer & Director |
| Dr. Badreddin Edris Ph.D. | Co-Founder & Independent Director |
| Dr. Behrad Derakhshan Ph.D. | Chief Business Officer |
| Dr. Joanne M. Donovan M.D., Ph.D. | Chief Medical Officer |
| Dr. Marc Semigran M.D. | Chief Development Officer |
| Dr. Peter A. Thompson FACP, M.D. | Co-Founder & Independent Chairman |
| John R. Moore J.D. | General Counsel |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 31, 2024 | 4 | Filing |
| Dec 27, 2024 | 4 | Filing |
| Dec 16, 2024 | 8-K | Current Report |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 14, 2024 | SC 13G | Statement of acquisition of beneficial ownership b... |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 12, 2024 | SC 13D/A | [Amend] Filing |
| Nov 12, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 08, 2024 | SC 13G | Statement of acquisition of beneficial ownership b... |